Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

TTA-A2

TTA-A2
TTA-A2 is a selective T-type calcium channel antagonist as a potent anticonvulsant that the Cav3.1 isoform plays a prominent role in mediating. TTA-A2 is equally potent against the Cav3.1 (a1G) and Cav3.2 (a1H) channels with IC50 values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy.
Catalog No. T8944Cas No. 953778-63-7
Select Batch
Purity:99.9%
Contact us for more batch information

Resource Download

TTA-A2

Catalog No. T8944Cas No. 953778-63-7

TTA-A2 is a selective T-type calcium channel antagonist as a potent anticonvulsant that the Cav3.1 isoform plays a prominent role in mediating. TTA-A2 is equally potent against the Cav3.1 (a1G) and Cav3.2 (a1H) channels with IC50 values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
1 mg$106In Stock
5 mg$268In Stock
10 mg$428In Stock
25 mg$785In Stock
50 mg$1,120In Stock
100 mg$1,480In Stock
1 mL x 10 mM (in DMSO)$295In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "TTA-A2"

Product Introduction

Bioactivity
Description
TTA-A2 is a selective T-type calcium channel antagonist as a potent anticonvulsant that the Cav3.1 isoform plays a prominent role in mediating. TTA-A2 is equally potent against the Cav3.1 (a1G) and Cav3.2 (a1H) channels with IC50 values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy.
Targets&IC50
Cav 3.1 (a1G):89 nM, Cav 3.2 (a1H):92 nM
In vivo
TTA-A2 (oral gavage; 10 mg/kg; once daily; 5 days) shows selective effect on recurrent thalamocortical network activity, it suppresses active wake and promotes slow-wave sleep in wild-type mice but not in mice lacking both Cav3.1 and Cav3.3[1].TTA-A2 (oral gavage;?3 mg/kg;?single dose) produces significant changes in sleep architecture in rats.?A reduction in active wake soon after dosing with a concurrent increase in delta sleep and decrease in REM sleep.?Additionally, these effects persists for up to 4 h post-dose in rats[2].
Chemical Properties
Molecular Weight378.39
FormulaC20H21F3N2O2
Cas No.953778-63-7
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 27.5 mg/mL (72.68 mM)
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.6428 mL13.2139 mL26.4278 mL132.1388 mL
5 mM0.5286 mL2.6428 mL5.2856 mL26.4278 mL
10 mM0.2643 mL1.3214 mL2.6428 mL13.2139 mL
20 mM0.1321 mL0.6607 mL1.3214 mL6.6069 mL
50 mM0.0529 mL0.2643 mL0.5286 mL2.6428 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy TTA-A2 | purchase TTA-A2 | TTA-A2 cost | order TTA-A2 | TTA-A2 chemical structure | TTA-A2 in vivo | TTA-A2 formula | TTA-A2 molecular weight